Background and Purpose-Sulfonylurea drugs inhibit ATP-dependent potassium channels and may increase mortality after myocardial infarction. Sulfonylurea drugs also inhibit ischemic preconditioning in experimental models of brain ischemia and in clinical studies in the human heart. Methods-In the present study we examined the impact of sulfonylurea drugs on in-hospital mortality and the immediate neurological deficit of diabetic stroke patients. From a larger stroke data bank, we studied 146 diabetic patients with acute hemispheric ischemic stroke. Sixty patients were using sulfonylurea drugs. 
D
iabetes mellitus increases the risk for coronary heart disease and ischemic stroke approximately 2-to 3-fold. 1,2 Diabetic or hyperglycemic patients have a worse prognosis and an increased mortality after stroke. [3] [4] [5] [6] Experimental models have shown that hyperglycemia increases damage after cerebral ischemia, probably by increasing acidosis-related damage. 7 Many diabetic patients are treated with oral sulfonylurea drugs, which depolarize pancreatic beta cells by inhibiting ATP-dependent potassium channels (K ATP ). This depolarization leads to calcium influx (similar to glucose binding) and finally to exocytosis of insulin-containing secretory granules. Some studies in the heart found that sulfonylurea drugs increase early and late mortality after myocardial ischemia in non-insulin-dependent patients with diabetes mellitus. 8 -10 However, these results have been repeatedly challenged by other authors. [11] [12] [13] The ongoing discussion about sulfonylurea drugs has been refocused by recent experimental observations that sulfonylurea drugs impair ischemic preconditioning. 14 K ATP are activated after brief hypoxic stimuli (which cause rapid ATP hydrolysis), hyperpolarize the cell, and confer resistance or tolerance against a subsequent prolonged hypoxic stress. Ischemic preconditioning can be simulated by agonists of K ATP and blocked when antagonists such as glibenclamide are applied. Similar effects have been observed in experimental brain ischemia. 15, 16 Sulfonylurea binding sites and K ATP are expressed in the human brain. 17, 18 However, whether sulfonylurea drugs in diabetic stroke patients affect immediate stroke severity, clinical course, and in-hospital mortality has not been examined to date. In this retrospective study we compared diabetic stroke patients with or without prior use of sulfonylurea drugs. Our results reveal no influence of common doses of sulfonylurea drugs in the immediate clinical outcome after ischemic stroke.
Subjects and Methods
The medical records of 439 consecutive patients with the diagnosis of acute stroke between January 1994 and May 2000 were reviewed. Patients were included if they met the following criteria: (1) acute ischemic deficits attributable to the anterior circulation and (2) diabetes as defined by repeated fasting plasma glucose Ͼ140 mg/dL, plasma glucose Ͼ200 mg/dL after glucose load or meals, or known or treated diabetes, according to the patient or referring physician. Patients who had no known diabetes and only transient hyperglyce-mia ("stress" hyperglycemia after stroke) were not included. After admission, hyperglycemia Ͼ150 to 160 mg/dL was treated by insulin, according to local stroke management guidelines, 19 irrespective of whether the patient had been treated with insulin before. Oral antidiabetic drugs were continued in 34 of 60 patients (57%). The remaining cases were treated with insulin. All patients received a CT scan, blood pressure and temperature measurement, and ECG immediately after admission and, depending on type and severity of the infarct, a repeated CT or MRI after 1 to 7 days to assess final infarct volume. Doppler/duplex sonography was performed, usually within 24 hours. Blood pressure was maintained within systolic values of 140 to 190 mm Hg by means of colloidal or starch infusion or, if elevated, by calcium antagonists or urapidil. Patients without contraindications received thrombolysis with recombinant tissue plasminogen activator within 3 hours. Heparin was administered intravenously in an unfractionated dose-adjusted manner in cases with presumed high stroke recurrence risk or low-flow conditions (atrial fibrillation, high-grade carotid stenosis, dissection) or with unfractionated heparin according to local stroke treatment guidelines.
Exclusion criteria were hemorrhagic stroke, subarachnoid hemorrhage, transient ischemic attacks (TIAs), and cerebral sinus thrombosis. Stroke etiologies were defined according to the Trial of Org 10172 in Acute Stroke Treatment (TOAST). 20 End points were as follows: (1) in-hospital case mortality rate; (2) motor impairment, assessed by the Canadian Neurological Scale (CNS) 21 ; (3) length of hospital stay; (4) requirement of intensive care; (5) clinical course within the first 72 hours after admission, derived from the medical record; (6) in-hospital complications (eg, pneumonia, urinary tract infection, recurrent stroke, hemorrhage); and (7) Rankin Scale score at follow-up (Ն3 months after stroke).
Cardiovascular risk factors were as follows: hypertension (blood pressure Ն140/90 mm Hg, 22 known or treated hypertension); peripheral vascular disease (intermittent claudication, ischemic rest pain, stenosis); ischemic heart disease (angina pectoris, previous myocardial infarction, coronary artery stenosis); lipid elevation (cholesterol Ͼ220 mg/dL, triglyceride elevation, or any lipid-lowering medication on admission); and atrial fibrillation (arrhythmia with no P wave on ECG, intermittent atrial fibrillation on Holter ECG, or known atrial fibrillation).
After discharge, patients were contacted by mail or telephone after at least 3 months to determine final outcome and were assessed by the Rankin score. 23 After data acquisition, diabetic stroke patients were stratified into 2 groups: a group that used sulfonylurea drugs and a group that did not.
Statistical Analysis
Frequencies and univariate comparisons were analyzed by 2 test for dichotomous variables and Wilcoxon U test for numeric variables. A backward stepwise logistic regression was used to correct for possible confounding factors for the end points. The following covariates were entered: sulfonylurea drug use, cardiovascular risk factors (hypertension, coronary artery disease, peripheral vascular disease, smoking, lipid elevation), age, sex, and stroke etiology.
Results
Of a total of 439 patients, 146 patients (33%) had diabetes and hemispheric stroke and were eligible for the study. Sixty patients were using sulfonylurea drugs at time of stroke onset as their only hypoglycemic drug.
The control group consisted of the remaining 86 diabetic stroke patients who did not use sulfonylurea drugs. The majority of these patients were treated with insulin, by diet alone, or with other oral glucose-lowering drugs such as acarbose or metformin. The majority of patients in the sulfonylurea group (53/60 [88%]) were treated with glibenclamide; 6 patients were treated with glimepiride and 1 with glibornuride. The mean daily dose of glibenclamide was 5.9Ϯ3.8 mg. The overall mortality of all diabetic stroke patients was 15 of 146 (10.3%), which was higher (but not significantly) than that in stroke patients without diabetes (18/293 [6.1%]; Pϭ0.12).
The baseline characteristics of the 2 groups are shown in Table 1 . There were no significant differences in the left/right distribution of the infarcts, cardiovascular risk factors (hypertension, ischemic heart disease, lipid elevation, smoking, TIAs), admission blood pressure, admission glucose and HbA 1c , and presumed stroke etiology according to TOAST criteria. There was a nonsignificant sex trend, with fewer women taking sulfonylurea drugs. The duration of diabetes was significantly longer in patients who were not using sulfonylurea drugs. The majority (71%) of patients in this group were using insulin.
The clinical end points are shown in Table 2 . Mortality rate and stroke severity (as measured by the validated CNS, in which low numbers indicate severe motor hemiparesis 24 ) were not different between the groups. All deaths were directly stroke related (transtentorial herniation due to edema or secondary hemorrhage). End points of in-hospital outcome were also not significantly different in the univariate analysis. Rankin score at follow-up (0 to 1, independent patients; 2 to 5, patients who have restrictions in lifestyle or are dependent), frequency of intensive care unit treatment, type of infarct on CT or MRI, length of hospital stay, and percentage of patients who could be discharged home did not differ between the groups. There was a nonsignificant trend toward neurological improvement in the sulfonylurea group, and more patients without sulfonylurea drugs had a fixed neurological deficit within the first 3 days. Next, a multivariate logistic regression analysis was performed to determine independent factors for death and severe stroke. For death, only smoking and the presence of peripheral vascular disease were independent predictors in the logistic regression. For severe stroke (as assessed by a CNS score Ͻ7), cardioembolism, lipid elevation, and peripheral vascular disease were independent predictors. Sulfonylurea drugs were not independent predictors for either end point (Table 3) . For deteriorating stroke, only coronary artery disease and smoking were independent factors.
To investigate other forms of preconditioning, we compared diabetic stroke patients with and without prodromal TIAs, as described. 25 Twenty-one patients had prodromal TIAs; these patients had fewer neurological deficits (mean CNS score, 8.2Ϯ2.3 versus 7.6Ϯ2.3; Pϭ0. 22 ) and an improved Rankin score (1.9Ϯ1.4 versus 3.2Ϯ1.8; Pϭ0.07), but the differences were not significant.
Discussion
In summary, we found no adverse in-hospital outcome of diabetic stroke patients who used sulfonylurea drugs before stroke. In addition, the in-hospital mortality rate was not increased in patients who used sulfonylurea drugs. This is in contrast to previous studies that showed increased mortality in this patient group. 8, 26 However, other observations also showed no increased mortality, 12 and cardiological studies usually are not designed to examine stroke, death after stroke, or stroke severity as primary end point. In the study of Jollis et al, 12 the rate of cerebrovascular disease also was not different: 15% in diabetics treated with sulfonylurea and 20% in patients treated with insulin. The differences might also be due to different classes of sulfonylurea drugs: in earlier studies many patients used tolbutamide, 10 in contrast to glibenclamide or other newer drugs such as glimepiride. One explanation of why some sulfonylurea drugs may have deleterious effects after stroke is that they may depolarize hypoxic neurons and favor neurotoxic cascades such as glutamate release and intracellular calcium increase. Experimental studies have also shown that ischemic tolerance in the brain is impaired by sulfonylurea drugs. 15, 16 Additionally, as in the heart, there is now evidence that ischemic tolerance occurs in the human brain. 25, 27 However, the relative action of sulfonylurea drugs depends on their ability to cross the blood-brain barrier, the receptor affinity, and spatial expression. Sulfonylureas bind to K ATP , which is a hetero-octameric complex consisting of 8 subunits. K ATP and sulfonylurea receptors are expressed in the human brain, 18, 28 but whether K ATP is involved in the regulation of vascular tone in the brain is not known. In humans, glibenclamide modulates peripheral vascular tone 29 but does not affect CO 2 -induced cerebral vasodilation. 30 In addition to pharmacological concerns, methodological errors must be taken into account. Since our study was hospital based and stroke has a high mortality, we cannot rule out that stroke patients with sulfonylurea drugs die before reaching the hospital; this is a general problem of hospital- ‡Complete middle cerebral artery (MCA) infarction: with or without involvement of basal ganglia; lacunar or pure subcortical: white matter infarcts Յ1.5 cm or small subcortical territorial infarcts such as anterior choroidal infarcts; partial MCA infarction: infarcts in the anterior or posterior superficial MCA territory, sparing the basal ganglia; unclassifiable: multiple infarcts or infarcts that do not fit either category, or cases in which initial CT was normal and follow-up CT was not performed because of benign clinical course.
§Intensive care unit (ICU) treatment necessary, usually because of impairment of consciousness, pneumonia, secondary deterioration, or secondary hemorrhagic stroke. based studies that might also explain outcome differences after myocardial infarction. 31 The mean dose of glibenclamide in the present study was lower than in other studies (5.9 versus 7.4 mg in the study of Klamann et al 13 ). Therefore, we cannot exclude that a possible deleterious effect was missed because of relative underuse of sulfonylurea drugs or lower dosage in our group.
Another reason that a difference was not detected between the groups may be that the control group was too heterogeneous: these patients were treated with insulin, with diet alone, or with acarbose or metformin. In some patients diabetes was not previously recognized.
Another shortcoming of our retrospective study is that use of sulfonylureas may be underreported or missed in the acute stroke setting. Conversely, we also cannot exclude noncompliance. Both cases might reduce the difference between the groups and finally lead to failure to detect a possible adverse effect of sulfonylurea drugs.
Despite the limitations of our small study, we conclude that sulfonylurea drugs were not associated with increased mortality or adverse clinical outcome in patients with diabetes and ischemic stroke. Despite concerns about sulfonylurea drugs because of increased mortality and impairment of ischemic preconditioning, glibenclamide and derivatives seem to be safe and had no impact on the immediate outcome after stroke in our study population.
